Liminal BioSciences (NASDAQ:LMNL; TSX:LMNL) presented two scientific posters with new preclinical data for its PBI-4050 drug candidate and the treatment of pulmonary arterial hypertension (PAH) at the American Heart Association annual conference in Philadelphia.
“Although not a current focus of the company’s research program, this new preclinical data adds to our body of knowledge of our lead compound, PBI-4050,” stated Kenneth Galbraith, CEO.
